Innovative Therapies for Glioblastoma Treatment

Glioblastoma remains one of the most aggressive primary brain tumours, characterised by rapid proliferation, diffuse infiltration and resistance to conventional modalities. Emerging therapeutic strategies harness a deeper understanding of tumour biology, the immune microenvironment and the blood–brain barrier to deliver more precise and effective interventions. These include RNA-based targeting platforms, synergistic drug combinations informed by large-scale molecular datasets, modulation of cell death pathways such as ferroptosis and autophagy, and repurposing of established agents to overcome chemoresistance. Together, these approaches aim to extend survival, improve quality of life and pave the way for personalised regimens informed by molecular profiling and real-time functional assays.

Research from Nature Portfolio

Recent studies have introduced selectively expressed RNA molecules (seRNAs) as a versatile platform for glioblastoma cell targeting. By combining antisense technology with mRNA secondary structures, seRNAs remain inert in normal cells and activate translation of therapeutic effectors only within glioblastoma cells. In proof-of-concept models, systemic delivery of seRNAs induced selective tumour cell death and significantly reduced intracranial tumour burden without detectable off-target effects, highlighting their potential for precision therapy.

Another advance employs a computational platform that integrates patient tumour gene expression profiles with large-scale perturbation datasets to identify synergistic drug pairs. This system computes disease discordance and drug concordance scores to nominate combinations of existing FDA-approved compounds predicted to act synergistically in glioblastoma. Preclinical validation demonstrated that this approach can uncover novel regimens that inhibit tumour cell viability more effectively than monotherapies, offering a rapid pathway to clinical translation.

Innovative Therapies for Glioblastoma Treatment publication trend

The graph below shows the total number of articles in innovative therapies for glioblastoma treatment across all publications each year (not limited to Nature Index journals).

Technical terms

seRNA: modular RNA construct that selectively activates translation of therapeutic effectors in targeted cells.

Ferroptosis: iron-dependent form of programmed cell death associated with lipid peroxidation.

Glioblastoma stem cell: subpopulation of tumour cells with self-renewal capacity thought to drive recurrence and resistance.

Temozolomide: alkylating chemotherapeutic agent that methylates DNA to induce tumour cell death.

References

1. Selectively expressed RNA molecules as a versatile tool for functionalized cell targeting. Nature Communications (2025).
2. Albumin-bound paclitaxel augment temozolomide treatment sensitivity of glioblastoma cells by disrupting DNA damage repair and promoting ferroptosis. Journal of Experimental & Clinical Cancer Research (2023).
3. Management of glioblastoma: State of the art and future directions. CA A Cancer Journal for Clinicians (2020).
4. Identification of thioridazine, an antipsychotic drug, as an antiglioblastoma and anticancer stem cell agent using public gene expression data. Cell Death & Disease (2015).
5. Drug and disease signature integration identifies synergistic combinations in glioblastoma. Nature Communications (2018).